SCHEMBL1408459

SCHEMBL1408459

COc1ccc(-c2c3cccc(F)c3nn2Cc2ccccc2Cl)c(C)c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 8/20 0.48
NR1H3 Q13133 8/20 0.48
NPBWR1 P48145 2/20 0.42
SLC16A3 O15427 5/20 0.42
SLC16A1 P53985 5/20 0.42
MCTS1 Q9ULC4 2/20 0.42
P2RX7 Q99572 2/20 0.42
NR1I2 O75469 2/20 0.41
NR3C1 P04150 2/20 0.41
AR P10275 1/20 0.41
RXRA P19793 1/20 0.41
KDM4E B2RXH2 1/20 0.39
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPT P10636 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1407454 0.92 NR1H2 (0.48) NR1H2NR1H3NPBWR1SLC16A3SLC16A1
SCHEMBL1408048 0.92 P2RX7 (0.48) NR1H2NR1H3NPBWR1P2RX7NR1I2
SCHEMBL1407762 0.90 NR1H2 (0.48) NR1H2NR1H3NPBWR1SLC16A3SLC16A1
SCHEMBL1408171 0.89 KMT2A (0.48) NR1H2NR1H3KDM4EALDH1A1HPGD
SCHEMBL1407200 0.88 NR1H2 (0.45) NR1H2NR1H3P2RX7ALDH1A1
SCHEMBL1407707 0.85 NR1H2 (0.43) NR1H2NR1H3P2RX7NR1I2NR3C1
SCHEMBL1407448 0.85 NR1H2 (0.47) NR1H2NR1H3P2RX7NR1I2NR3C1
SCHEMBL1414643 0.82 NR1H2 (0.48) NR1H2NR1H3NPBWR1P2RX7NR1I2
SCHEMBL1407466 0.82 NR1H2 (0.47) NR1H2NR1H3P2RX7NR1I2NR3C1
SCHEMBL1407447 0.82 NR1H2 (0.47) NR1H2NR1H3NPBWR1P2RX7NR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US claimed
EP-1773781-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES Wyeth (US) 2007-04-18 EP claimed
WO-2006017384-A2 INDAZOLES USEFUL IN TREATING CARDIOVASCULAR DISEASES WYETH (US) 2006-02-16 WO claimed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US claimed
EP-2295429-A1 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases Wyeth LLC (US) 2011-03-16 EP disclosed
US-7592363-B2 Indazoles WYETH (US) 2009-09-22 US disclosed
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases WYETH (US) 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030612-A1 Indazoles useful in treating cardiovascular diseases NR1H2, NR1H3, CYP46A1 NR1H2 1/4885NR1H3 2/4885NPBWR1 1966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.